Teva still targets Mylan despite rejection

Mylan had unanimously rejected Tea’s bid to acquire it for roughly $41 billion earlier in the week.

By GLOBES
May 4, 2015 12:00
1 minute read.
The Teva Pharmaceutical Industries

The Teva Pharmaceutical Industries plant in Jerusalem.. (photo credit: AMIR COHEN - REUTERS)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceuticals on Wednesday doubled down on its attempt to acquire its rival Mylan despite being rebuffed by Mylan’s board, which it accused of “mudslinging.”

“I firmly believe that our respective stakeholders do not support, or benefit from, mudslinging, mis-characterization, rehashing of history or selective presentation of facts,” Teva wrote in a letter to Mylan chairman Robert J. Coury.

Be the first to know - Join our Facebook page.


Mylan had unanimously rejected Tea’s bid to acquire it for roughly $41 billion earlier in the week.

In a statement, Coury had said: “Teva’s proposal grossly undervalues Mylan and would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk.”

He also said Teva’s board and leadership team had “a poor record of delivering sustainable shareholder value.”

Teva’s letter on Wednesday said it was “disappointed,” given that the two companies had had a “constructive” meeting. It did not amend its offer. Mylan’s references to “Teva’s proposal grossly undervalues Mylan” could indicate that it could be playing hard to get so that Teva would jack up the offer, the letter said.

Meanwhile, Mylan renewed its own bid to take over Perrigo, another Israeli pharmaceutical company, which had rejected a previous takeover bid by Mylan.


Related Content

CANCER PATIENTS sit in a chemotherapy ward while receiving treatment at the Korle Bu Teaching Hospit
July 17, 2018
Cancer-treatment drug gets name from the Torah

By OREN OPPENHEIM, ROCKY BAIER